"pediatric tuberculosis"[MeSH Terms] AND "diagnosis"[MeSH Terms]

"tuberculosis"[MeSH Terms] AND "child"[MeSH Terms] AND "treatment"

mkdir -p /home/daytona/workspace/paediatric-tb && ls /home/daytona/workspace/pae…

~/paediatric-tb/generate.js

const {
  Document, Packer, Paragraph, TextRun, Table, TableRow, TableCell,
  HeadingLevel, AlignmentType, BorderStyle, WidthType, ShadingType,
  VerticalAlign, PageNumber, Header, Footer, TabStopType, TabStopPosition,
  PageBreak
} = require('docx');
const fs = require('fs');

// ── Colour palette ──────────────────────────────────────────────────────────
const NAVY   = "1F3864";  // deep navy – headings
const TEAL   = "0D6B6E";  // teal – section bars
const LTBLUE = "D9E8F5";  // light blue – table header shading
const LTGREY = "F2F2F2";  // light grey – alternate table rows
const WHITE  = "FFFFFF";
const BLACK  = "000000";
const RED    = "C0392B";  // warning text
const ORANGE = "D35400";  // highlight

// ── Helper: Coloured section heading bar ────────────────────────────────────
function sectionHeading(text) {
  return new Paragraph({
    spacing: { before: 280, after: 100 },
    shading: { type: ShadingType.SOLID, color: TEAL, fill: TEAL },
    indent: { left: 0 },
    children: [
      new TextRun({
        text: text.toUpperCase(),
        bold: true,
        color: WHITE,
        size: 22,
        font: "Calibri"
      })
    ]
  });
}

// ── Helper: Sub-heading ──────────────────────────────────────────────────────
function subHeading(text) {
  return new Paragraph({
    spacing: { before: 180, after: 60 },
    children: [
      new TextRun({
        text,
        bold: true,
        color: NAVY,
        size: 21,
        font: "Calibri"
      })
    ]
  });
}

// ── Helper: Body paragraph ───────────────────────────────────────────────────
function body(text, { bold = false, italic = false, color = BLACK, indent = 0 } = {}) {
  return new Paragraph({
    spacing: { after: 80 },
    indent: { left: indent },
    children: [
      new TextRun({ text, bold, italic, color, size: 20, font: "Calibri" })
    ]
  });
}

// ── Helper: Bullet ───────────────────────────────────────────────────────────
function bullet(text, level = 0) {
  return new Paragraph({
    bullet: { level },
    spacing: { after: 60 },
    indent: { left: 360 + level * 360 },
    children: [
      new TextRun({ text, size: 20, font: "Calibri", color: BLACK })
    ]
  });
}

// ── Helper: Warning box ──────────────────────────────────────────────────────
function warningBox(text) {
  return new Paragraph({
    spacing: { before: 140, after: 140 },
    shading: { type: ShadingType.SOLID, color: "FFF3CD", fill: "FFF3CD" },
    border: {
      left: { style: BorderStyle.SINGLE, size: 18, color: ORANGE }
    },
    indent: { left: 200 },
    children: [
      new TextRun({ text: "⚠  " + text, size: 20, font: "Calibri", color: ORANGE, bold: true })
    ]
  });
}

// ── Helper: simple table ─────────────────────────────────────────────────────
function makeTable(headers, rows, colWidths) {
  const headerRow = new TableRow({
    tableHeader: true,
    children: headers.map((h, i) =>
      new TableCell({
        width: { size: colWidths[i], type: WidthType.DXA },
        shading: { type: ShadingType.SOLID, color: NAVY, fill: NAVY },
        verticalAlign: VerticalAlign.CENTER,
        children: [new Paragraph({
          alignment: AlignmentType.CENTER,
          children: [new TextRun({ text: h, bold: true, color: WHITE, size: 19, font: "Calibri" })]
        })]
      })
    )
  });

  const dataRows = rows.map((row, ri) =>
    new TableRow({
      children: row.map((cell, ci) =>
        new TableCell({
          width: { size: colWidths[ci], type: WidthType.DXA },
          shading: { type: ShadingType.SOLID, color: ri % 2 === 0 ? WHITE : LTGREY, fill: ri % 2 === 0 ? WHITE : LTGREY },
          verticalAlign: VerticalAlign.CENTER,
          children: [new Paragraph({
            children: [new TextRun({ text: String(cell), size: 19, font: "Calibri", color: BLACK })]
          })]
        })
      )
    })
  );

  return new Table({
    width: { size: 9026, type: WidthType.DXA },
    rows: [headerRow, ...dataRows]
  });
}

// ── Helper: spacer ───────────────────────────────────────────────────────────
function spacer(size = 100) {
  return new Paragraph({ spacing: { after: size }, children: [] });
}

// ═══════════════════════════════════════════════════════════════════════════
// DOCUMENT CONTENT
// ═══════════════════════════════════════════════════════════════════════════

const children = [

  // ── TITLE BLOCK ────────────────────────────────────────────────────────
  new Paragraph({
    spacing: { before: 0, after: 80 },
    shading: { type: ShadingType.SOLID, color: NAVY, fill: NAVY },
    alignment: AlignmentType.CENTER,
    children: [
      new TextRun({ text: "PAEDIATRIC TUBERCULOSIS", bold: true, color: WHITE, size: 36, font: "Calibri" })
    ]
  }),
  new Paragraph({
    spacing: { after: 60 },
    shading: { type: ShadingType.SOLID, color: TEAL, fill: TEAL },
    alignment: AlignmentType.CENTER,
    children: [
      new TextRun({ text: "Clinical Summary: Screening, Diagnosis & Treatment", color: WHITE, size: 22, font: "Calibri", italic: true })
    ]
  }),
  new Paragraph({
    spacing: { after: 20 },
    shading: { type: ShadingType.SOLID, color: LTBLUE, fill: LTBLUE },
    alignment: AlignmentType.CENTER,
    children: [
      new TextRun({ text: "Sources: Park's Textbook of Preventive & Social Medicine  |  Harriet Lane Handbook 23rd Ed. (Johns Hopkins)  |  WHO / NTEP / AAP Guidelines", color: NAVY, size: 17, font: "Calibri" })
    ]
  }),
  spacer(200),

  // ══════════════════════════════════════════════════════════════════════
  // 1. EPIDEMIOLOGY
  // ══════════════════════════════════════════════════════════════════════
  sectionHeading("1. Epidemiology & Risk Factors"),

  subHeading("Burden"),
  bullet("Children <15 years = 6–8% of all TB cases globally"),
  bullet("Most common age group: 1–4 years"),
  bullet("Children are rarely sputum smear-positive; they are not significant sources of transmission"),
  bullet("Childhood TB largely reflects failure of adult TB control in the community"),
  spacer(80),

  subHeading("Risk Factors for Infection & Progression"),
  makeTable(
    ["Risk Category", "Specific Risk Factors"],
    [
      ["Age", "< 5 years: up to 20% progress to disease within 2 years of infection"],
      ["Exposure", "Household contact with smear-positive PTB; infant of TB-positive mother"],
      ["Immunity", "HIV infection, malnutrition, immunosuppressive therapy (steroids, TNF-blockers)"],
      ["Comorbidities", "Cancer, diabetes mellitus, chronic renal failure, nephrotic syndrome"],
      ["Geography", "Born in / travelled to TB-endemic country"],
      ["Dissemination", "Young age is the principal risk factor for miliary TB and TB meningitis"]
    ],
    [2500, 6526]
  ),
  spacer(200),

  // ══════════════════════════════════════════════════════════════════════
  // 2. CLINICAL FEATURES
  // ══════════════════════════════════════════════════════════════════════
  sectionHeading("2. Clinical Features"),

  subHeading("Cardinal Symptoms (Presumptive TB – NTEP Criteria)"),
  bullet("Persistent fever ≥ 2 weeks without a known cause"),
  bullet("Unremitting cough ≥ 2 weeks"),
  bullet("Weight loss ≥ 5% in 3 months OR no weight gain in the past 3 months"),
  spacer(80),

  subHeading("Pulmonary TB"),
  bullet("Hilar / mediastinal lymphadenopathy (most common CXR finding)"),
  bullet("Consolidation, miliary pattern, chronic fibrocavitatory shadows"),
  bullet("Children rarely produce sputum – gastric aspirate is often required"),
  spacer(80),

  subHeading("Extrapulmonary TB (EPTB) – more common in children than adults"),
  makeTable(
    ["Site", "Features"],
    [
      ["Peripheral lymphadenitis", "Most common EPTB; cervical nodes most frequent; may suppurate"],
      ["TB meningitis", "Severe headache, vomiting, altered sensorium, neck stiffness; high mortality"],
      ["Miliary TB", "Diffuse miliary nodules on CXR; fever, hepatosplenomegaly"],
      ["Pleural TB", "Exudative pleural effusion; TST usually positive"],
      ["Abdominal TB", "Ascites, lymphadenopathy, obstruction"],
      ["Osteoarticular TB", "Pott's disease (spine), joint swelling, limp"]
    ],
    [2800, 6226]
  ),
  spacer(200),

  // ══════════════════════════════════════════════════════════════════════
  // 3. SCREENING
  // ══════════════════════════════════════════════════════════════════════
  sectionHeading("3. Screening"),

  subHeading("AAP / Harriet Lane Screening Approach"),
  body("Complete at-risk assessment at: first well-child visit → every 6 months in year 1 → then annually."),
  spacer(60),

  subHeading("Screen if Any of the Following Apply"),
  bullet("Born outside US / travelled to TB-endemic country"),
  bullet("Family member with positive TST or known TB exposure"),
  bullet("Exposed to person with active TB disease"),
  bullet("On immunosuppressive therapy (e.g. TNF-blockers, steroids)"),
  bullet("Household contact with a person who: was incarcerated, uses illegal drugs, is HIV-positive"),
  bullet("Consumes unpasteurised milk or milk products"),
  spacer(200),

  // ══════════════════════════════════════════════════════════════════════
  // 4. DIAGNOSTIC TESTS
  // ══════════════════════════════════════════════════════════════════════
  sectionHeading("4. Diagnostic Tests"),

  subHeading("4a. Tuberculin Skin Test (TST / Mantoux)"),
  body("India: 2 TU PPD RT23 intradermally; read at 48–72 h. USA (AAP): standard PPD 5 TU."),
  spacer(60),
  body("Threshold for a POSITIVE result (Harriet Lane / AAP criteria):", { bold: true }),
  spacer(40),
  makeTable(
    ["Induration", "Population"],
    [
      ["≥ 5 mm", "Close TB contact; suspected active TB; immunosuppressed / HIV-positive"],
      ["≥ 10 mm", "Age < 4 yrs; cancer, DM, CRF, malnutrition; born in / travelled to endemic country; contact with high-risk adults"],
      ["≥ 15 mm", "Children ≥ 4 years with NO risk factors"]
    ],
    [1400, 7626]
  ),
  spacer(120),

  subHeading("4b. Interferon Gamma Release Assays (IGRAs)"),
  bullet("QuantiFERON-TB Gold In-Tube and T-SPOT.TB"),
  bullet("High specificity; not affected by prior BCG vaccination"),
  bullet("Can be used in children ≥ 2 years old"),
  bullet("Preferred over TST in BCG-vaccinated children in low-incidence settings"),
  spacer(80),

  subHeading("4c. Microbiological Tests"),
  makeTable(
    ["Test", "Specimen", "Key Points"],
    [
      ["CBNAAT (GeneXpert)", "Sputum / GA / IS / BAL", "PREFERRED first-line; detects rifampicin resistance; result in ~2 hrs"],
      ["Smear microscopy (ZN / fluorescent)", "Sputum (≥2 samples)", "Use if CBNAAT unavailable; low sensitivity in children"],
      ["Liquid culture (MGIT)", "Any specimen", "Gold standard; result in 1–6 weeks"],
      ["Solid culture (LJ medium)", "Any specimen", "Up to 10 weeks; DST available"],
      ["Nucleic acid amplification", "Various", "Rapid; may also detect rifampicin resistance"]
    ],
    [2200, 2800, 4026]
  ),
  spacer(80),
  body("Specimen sources: sputum, gastric aspirate (morning x3), induced sputum, BAL, pleural fluid, CSF, urine, tissue biopsy."),
  spacer(80),

  subHeading("4d. Radiology"),
  bullet("Chest X-ray: FIRST imaging step after positive screening test"),
  bullet("Highly suggestive CXR findings: hilar/mediastinal lymphadenopathy, miliary pattern, fibrocavitatory shadows"),
  bullet("CT chest: preferred over CXR when active disease is suspected (Harriet Lane)"),
  bullet("Non-specific CXR: consolidations, bronchopneumonia patterns – may require further workup"),
  spacer(80),

  subHeading("4e. CSF / Lumbar Puncture"),
  bullet("Mandatory in all children < 12 months with confirmed TB"),
  bullet("Consider in children > 12 months with neurological signs/symptoms"),
  spacer(80),

  warningBox("Do NOT use fluoroquinolones, linezolid, or amoxicillin-clavulanate as empiric antibiotics – they have anti-TB activity and will confound diagnosis and DST results."),
  spacer(200),

  // ══════════════════════════════════════════════════════════════════════
  // 5. DIAGNOSTIC ALGORITHM SUMMARY
  // ══════════════════════════════════════════════════════════════════════
  sectionHeading("5. Diagnostic Algorithm (NTEP / RNTCP – Pulmonary TB)"),

  makeTable(
    ["Step", "Action"],
    [
      ["Presumptive TB", "Fever ≥2 wks AND/OR cough ≥2 wks AND/OR weight loss ≥5% in 3 months"],
      ["Step 1", "CBNAAT on sputum → MTB detected = Microbiologically confirmed TB → start treatment"],
      ["Step 2 (if CBNAAT –ve or no specimen)", "Chest X-ray + TST (Mantoux 2 TU PPD RT23)"],
      ["CXR highly suggestive", "Gastric aspirate / induced sputum for CBNAAT → +ve = confirmed; –ve = clinically diagnosed TB"],
      ["CXR NS shadows + TST –ve", "Trial of non-TB antibiotics → if shadows persist → gastric aspirate/IS for CBNAAT"],
      ["CXR normal + TST +ve", "Evaluate for EPTB; refer to specialist"],
      ["CXR normal + TST –ve", "Look for alternative diagnosis"],
      ["Rif-resistance on CBNAAT", "Manage as DR-TB; refer to DR-TB centre"]
    ],
    [2000, 7026]
  ),
  spacer(80),
  body("Note: This algorithm applies only to drug-sensitive TB suspects (no prior ATT, not MDR/RR-TB contacts).", { italic: true, color: "666666" }),
  spacer(80),
  warningBox("All confirmed TB cases must be offered HIV testing."),
  spacer(200),

  // ══════════════════════════════════════════════════════════════════════
  // 6. TREATMENT – DRUG-SENSITIVE TB
  // ══════════════════════════════════════════════════════════════════════
  sectionHeading("6. Treatment – Drug-Sensitive TB"),

  subHeading("Standard Regimen"),
  makeTable(
    ["Phase", "Duration", "Drugs", "Notes"],
    [
      ["Intensive", "2 months", "Isoniazid + Rifampicin + Pyrazinamide + Ethambutol (HRZE)", "Daily under DOT"],
      ["Continuation", "4 months", "Isoniazid + Rifampicin (HR)", "Daily under DOT"],
      ["Total", "6 months", "—", "India: paediatric patient-wise fixed-dose boxes by weight band"]
    ],
    [1500, 1300, 3800, 2426]
  ),
  spacer(120),

  subHeading("WHO Recommended Paediatric Drug Doses (< 30 kg)"),
  makeTable(
    ["Drug", "Daily Dose", "Max Dose"],
    [
      ["Isoniazid (H)", "7–15 mg/kg", "300 mg"],
      ["Rifampicin (R)", "10–20 mg/kg", "600 mg"],
      ["Pyrazinamide (Z)", "30–40 mg/kg", "2000 mg"],
      ["Ethambutol (E)", "15–25 mg/kg once daily", "—"]
    ],
    [2800, 3000, 3226]
  ),
  spacer(200),

  // ══════════════════════════════════════════════════════════════════════
  // 7. TREATMENT – LATENT TB INFECTION (LTBI)
  // ══════════════════════════════════════════════════════════════════════
  sectionHeading("7. Treatment – Latent TB Infection (LTBI)"),

  body("Step 1: Always rule out active TB before starting LTBI treatment."),
  spacer(80),

  subHeading("AAP / Harriet Lane Recommended Regimens"),
  makeTable(
    ["Regimen", "Duration", "Preferred?"],
    [
      ["Rifampin (R) alone", "4 months daily", "Preferred, especially ≤ 5 years"],
      ["Isoniazid + Rifapentine (3HP) – weekly", "12 weeks", "Preferred if ≥ 2 years of age"],
      ["Isoniazid (H) alone", "9 months daily", "Alternative"],
      ["Isoniazid + Rifampin (HR)", "3 months daily", "Alternative"]
    ],
    [2800, 2400, 3826]
  ),
  spacer(120),

  subHeading("NTEP / India: TB Preventive Therapy (TPT) Indications"),
  body("INH dose: 10 mg/kg/day for 6 months. Indicated for:"),
  bullet("Asymptomatic contacts < 6 years of a smear-positive PTB case (after ruling out active disease, regardless of BCG/nutritional status)"),
  bullet("HIV-infected children with known TB exposure OR TST positive (≥ 5 mm) without active TB"),
  bullet("TST-positive children on immunosuppressive therapy (e.g., nephrotic syndrome, acute leukaemia)"),
  bullet("Neonate born to a mother diagnosed with TB in pregnancy (after ruling out congenital TB) – followed by BCG vaccination after 6 months"),
  spacer(200),

  // ══════════════════════════════════════════════════════════════════════
  // 8. TREATMENT – DRUG-RESISTANT TB
  // ══════════════════════════════════════════════════════════════════════
  sectionHeading("8. Treatment – Drug-Resistant TB (DR-TB)"),

  subHeading("Principles"),
  bullet("Always treat in consultation with a DR-TB specialist"),
  bullet("Include at least 4–6 bactericidal drugs to which the strain is known/likely susceptible"),
  bullet("Never add a single drug to a failing regimen"),
  bullet("Treat for ≥ 12 months after culture conversion to negative"),
  bullet("Extend to 24 months for HIV co-infection or cavitatory lesions"),
  spacer(80),

  subHeading("Selected WHO Paediatric DR-TB Drug Doses"),
  makeTable(
    ["Drug", "Paediatric Dose"],
    [
      ["Levofloxacin (≤ 5 yrs)", "15–20 mg/kg/day in 2 divided doses"],
      ["Levofloxacin (> 5 yrs)", "10–15 mg/kg once daily"],
      ["Moxifloxacin", "7.5–10 mg/kg once daily"],
      ["Linezolid", "10 mg/kg 3× daily (+ pyridoxine B6)"],
      ["Cycloserine", "10–20 mg/kg/day"],
      ["Ethionamide / Protionamide", "15–20 mg/kg/day"],
      ["Meropenem (IV)", "20–40 mg/kg every 8 hours"],
      ["p-Aminosalicylic acid", "200–300 mg/kg/day (< 30 kg)"],
      ["Amikacin / Kanamycin / Capreomycin", "15–30 mg/kg once daily (max 1000 mg)"]
    ],
    [3500, 5526]
  ),
  spacer(200),

  // ══════════════════════════════════════════════════════════════════════
  // 9. TB-HIV CO-INFECTION
  // ══════════════════════════════════════════════════════════════════════
  sectionHeading("9. TB-HIV Co-Infection in Children"),

  bullet("HIV dramatically increases risk of TB infection progressing to disseminated disease and death"),
  bullet("TST threshold is reduced to ≥ 5 mm in HIV-positive children"),
  bullet("Both TB and HIV must be treated simultaneously; monitor for drug interactions (rifampicin strongly induces CYP450 – affects ART levels)"),
  bullet("TPT with INH 10 mg/kg/day for 6 months is indicated for all HIV-positive children with TB exposure or positive TST without active disease"),
  bullet("All TB-diagnosed children must be tested for HIV"),
  spacer(200),

  // ══════════════════════════════════════════════════════════════════════
  // 10. BCG VACCINATION
  // ══════════════════════════════════════════════════════════════════════
  sectionHeading("10. BCG Vaccination"),

  bullet("BCG given at birth provides strong protection against severe childhood TB: TB meningitis and miliary TB"),
  bullet("Does not reliably prevent pulmonary TB in adults"),
  bullet("After LTBI prophylaxis in a neonate of a TB-positive mother: give 6 months INH → then BCG vaccination"),
  bullet("BCG scar failure does not require re-vaccination if the child is in a high-burden country (vaccination was effective)"),
  spacer(200),

  // ══════════════════════════════════════════════════════════════════════
  // 11. MONITORING & FOLLOW-UP
  // ══════════════════════════════════════════════════════════════════════
  sectionHeading("11. Monitoring During Treatment"),

  makeTable(
    ["Parameter", "Frequency / Notes"],
    [
      ["Weight & clinical response", "Every 2–4 weeks; dose-adjust at each weight band threshold"],
      ["Sputum smear / culture", "End of intensive phase (month 2), month 5, end of treatment"],
      ["Chest X-ray", "End of treatment; or if clinical deterioration"],
      ["Liver function (if symptomatic)", "Isoniazid, rifampicin, pyrazinamide are hepatotoxic – monitor if symptomatic"],
      ["Pyridoxine (B6) supplementation", "Give with INH if malnourished, HIV-positive, or breastfeeding"],
      ["DOT compliance", "Every dose under direct observation until treatment completion"]
    ],
    [3000, 6026]
  ),
  spacer(200),

  // ══════════════════════════════════════════════════════════════════════
  // 12. KEY REFERENCES
  // ══════════════════════════════════════════════════════════════════════
  sectionHeading("12. References & Sources"),

  bullet("Park's Textbook of Preventive and Social Medicine – RNTCP / NTEP Paediatric TB Guidelines, pp. 218–230"),
  bullet("The Harriet Lane Handbook, 23rd Edition – The Johns Hopkins Hospital, pp. 620–621 (AAP / WHO Recommendations)"),
  bullet("WHO Guidelines for Treatment of Drug-Susceptible Tuberculosis, 2022 Update"),
  bullet("Martinez L et al. Effectiveness of preventive treatment across age groups. Lancet Respir Med. 2024 Aug. [PMID: 38734022]"),
  bullet("Duong T et al. Levofloxacin for contacts of MDR-TB. NEJM Evid. 2025 Jan. [PMID: 39693627]"),
  spacer(100),
  new Paragraph({
    spacing: { before: 200 },
    alignment: AlignmentType.CENTER,
    children: [
      new TextRun({ text: "Clinical Summary Document  |  Prepared by Orris  |  July 2026", size: 17, font: "Calibri", color: "888888", italic: true })
    ]
  })
];

// ── Build & write document ──────────────────────────────────────────────────
const doc = new Document({
  creator: "Orris Clinical AI",
  title: "Paediatric Tuberculosis – Clinical Summary",
  description: "Clinical summary covering screening, diagnosis and treatment of paediatric TB",
  styles: {
    default: {
      document: {
        run: { font: "Calibri", size: 20 }
      }
    }
  },
  sections: [{
    properties: {
      page: {
        margin: { top: 720, bottom: 720, left: 900, right: 900 }
      }
    },
    headers: {
      default: new Header({
        children: [
          new Paragraph({
            shading: { type: ShadingType.SOLID, color: NAVY, fill: NAVY },
            children: [
              new TextRun({ text: "PAEDIATRIC TUBERCULOSIS – Clinical Summary", bold: true, color: WHITE, size: 18, font: "Calibri" }),
              new TextRun({ text: "   |   Orris Clinical AI  |  July 2026", color: "AAAAAA", size: 17, font: "Calibri" })
            ]
          })
        ]
      })
    },
    footers: {
      default: new Footer({
        children: [
          new Paragraph({
            alignment: AlignmentType.CENTER,
            children: [
              new TextRun({ text: "Page ", size: 17, font: "Calibri", color: "888888" }),
              new PageNumber()
            ]
          })
        ]
      })
    },
    children
  }]
});

Packer.toBuffer(doc).then(buffer => {
  fs.writeFileSync("/home/daytona/workspace/paediatric-tb/Paediatric_TB_Clinical_Summary.docx", buffer);
  console.log("✓ Document written successfully.");
}).catch(err => {
  console.error("Error:", err);
  process.exit(1);
});

cd /home/daytona/workspace/paediatric-tb && node generate.js

cd /home/daytona/workspace/paediatric-tb && node -e "const d = require('docx'); …

cd /home/daytona/workspace/paediatric-tb && node -e "const {PageNumber, PageNumb…

~/paediatric-tb/generate.js

Error: String not found in file: '        PageNumber, PageBreak
} = require('docx');'

~/paediatric-tb/generate.js

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/paediatric-tb/generate.js'

~/paediatric-tb/generate.js

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/paediatric-tb/generate.js'

cd /home/daytona/workspace/paediatric-tb && node generate.js

python /home/daytona/skills/docx/scripts/office/validate.py /home/daytona/worksp…

python3 -c " import zipfile, os path = '/home/daytona/workspace/paediatric-tb/Pa…